AustralieFrV1, PubMed, Curation, bibRecord, 000624

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Identifieur interne : 000624 ( PubMed/Curation ); précédent : 000623; suivant : 000625

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Auteurs : Yulong Gao [Australie] ; Fernando Souza-Fonseca-Guimaraes [Australie] ; Tobias Bald [Australie] ; Susanna S. Ng [Australie] ; Arabella Young [Australie] ; Shin Foong Ngiow [Australie] ; Jai Rautela [Australie] ; Jasmin Straube [Australie] ; Nic Waddell [Australie] ; Stephen J. Blake [Australie] ; Juming Yan [Australie] ; Laurent Bartholin [France] ; Jason S. Lee [Australie] ; Eric Vivier [France] ; Kazuyoshi Takeda [Japon] ; Meriem Messaoudene [France] ; Laurence Zitvogel [France] ; Michele W L. Teng [Australie] ; Gabrielle T. Belz [Australie] ; Christian R. Engwerda [Australie] ; Nicholas D. Huntington [Australie] ; Kyohei Nakamura [Australie] ; Michael Hölzel [Allemagne] ; Mark J. Smyth [Australie]

Source :

Nature immunology [ 1529-2916 ] ; 2017.

RBID : pubmed:28759001

Descripteurs français

English descriptors

KwdEn :
- Animals, Case-Control Studies, Cell Line, Tumor, Cellular Reprogramming (immunology), Enzyme-Linked Immunosorbent Assay, Fibrosarcoma (immunology), Flow Cytometry, Gastrointestinal Neoplasms (immunology), Gastrointestinal Stromal Tumors (immunology), Gene Expression Profiling, Humans, Immunity, Innate (immunology), Killer Cells, Natural (cytology), Killer Cells, Natural (immunology), Lymphocytes (cytology), Lymphocytes (immunology), Mice, Neoplasms, Experimental (immunology), Sequence Analysis, RNA, Signal Transduction, Transforming Growth Factor beta (immunology), Tumor Escape (immunology).
MESH :
- chemical , immunology : Transforming Growth Factor beta.
- cytology : Killer Cells, Natural, Lymphocytes.
- immunology : Cellular Reprogramming, Fibrosarcoma, Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors, Immunity, Innate, Killer Cells, Natural, Lymphocytes, Neoplasms, Experimental, Tumor Escape.
- Animals, Case-Control Studies, Cell Line, Tumor, Enzyme-Linked Immunosorbent Assay, Flow Cytometry, Gene Expression Profiling, Humans, Mice, Sequence Analysis, RNA, Signal Transduction.

Abstract

Avoiding destruction by immune cells is a hallmark of cancer, yet how tumors ultimately evade control by natural killer (NK) cells remains incompletely defined. Using global transcriptomic and flow-cytometry analyses and genetically engineered mouse models, we identified the cytokine-TGF-β-signaling-dependent conversion of NK cells (CD49a(-)CD49b(+)Eomes(+)) into intermediate type 1 innate lymphoid cell (intILC1) (CD49a(+)CD49b(+)Eomes(+)) populations and ILC1 (CD49a(+)CD49b(-)Eomes(int)) populations in the tumor microenvironment. Strikingly, intILC1s and ILC1s were unable to control local tumor growth and metastasis, whereas NK cells favored tumor immunosurveillance. Experiments with an antibody that neutralizes the cytokine TNF suggested that escape from the innate immune system was partially mediated by TNF-producing ILC1s. Our findings provide new insight into the plasticity of group 1 ILCs in the tumor microenvironment and suggest that the TGF-β-driven conversion of NK cells into ILC1s is a previously unknown mechanism by which tumors escape surveillance by the innate immune system.

DOI: 10.1038/ni.3800
PubMed: 28759001

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000626

Links to Exploration step

pubmed:28759001

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.</title>
<author><name sortKey="Gao, Yulong" sort="Gao, Yulong" uniqKey="Gao Y" first="Yulong" last="Gao">Yulong Gao</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Souza Fonseca Guimaraes, Fernando" sort="Souza Fonseca Guimaraes, Fernando" uniqKey="Souza Fonseca Guimaraes F" first="Fernando" last="Souza-Fonseca-Guimaraes">Fernando Souza-Fonseca-Guimaraes</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bald, Tobias" sort="Bald, Tobias" uniqKey="Bald T" first="Tobias" last="Bald">Tobias Bald</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ng, Susanna S" sort="Ng, Susanna S" uniqKey="Ng S" first="Susanna S" last="Ng">Susanna S. Ng</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ngiow, Shin Foong" sort="Ngiow, Shin Foong" uniqKey="Ngiow S" first="Shin Foong" last="Ngiow">Shin Foong Ngiow</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rautela, Jai" sort="Rautela, Jai" uniqKey="Rautela J" first="Jai" last="Rautela">Jai Rautela</name>
<affiliation wicri:level="1"><nlm:affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Straube, Jasmin" sort="Straube, Jasmin" uniqKey="Straube J" first="Jasmin" last="Straube">Jasmin Straube</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Waddell, Nic" sort="Waddell, Nic" uniqKey="Waddell N" first="Nic" last="Waddell">Nic Waddell</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Blake, Stephen J" sort="Blake, Stephen J" uniqKey="Blake S" first="Stephen J" last="Blake">Stephen J. Blake</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yan, Juming" sort="Yan, Juming" uniqKey="Yan J" first="Juming" last="Yan">Juming Yan</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bartholin, Laurent" sort="Bartholin, Laurent" uniqKey="Bartholin L" first="Laurent" last="Bartholin">Laurent Bartholin</name>
<affiliation wicri:level="1"><nlm:affiliation>Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Jason S" sort="Lee, Jason S" uniqKey="Lee J" first="Jason S" last="Lee">Jason S. Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Control of Gene Expression Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Control of Gene Expression Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vivier, Eric" sort="Vivier, Eric" uniqKey="Vivier E" first="Eric" last="Vivier">Eric Vivier</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Takeda, Kazuyoshi" sort="Takeda, Kazuyoshi" uniqKey="Takeda K" first="Kazuyoshi" last="Takeda">Kazuyoshi Takeda</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cell Biology, Biomedical Research Center and Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Cell Biology, Biomedical Research Center and Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Messaoudene, Meriem" sort="Messaoudene, Meriem" uniqKey="Messaoudene M" first="Meriem" last="Messaoudene">Meriem Messaoudene</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Belz, Gabrielle T" sort="Belz, Gabrielle T" uniqKey="Belz G" first="Gabrielle T" last="Belz">Gabrielle T. Belz</name>
<affiliation wicri:level="1"><nlm:affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Engwerda, Christian R" sort="Engwerda, Christian R" uniqKey="Engwerda C" first="Christian R" last="Engwerda">Christian R. Engwerda</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huntington, Nicholas D" sort="Huntington, Nicholas D" uniqKey="Huntington N" first="Nicholas D" last="Huntington">Nicholas D. Huntington</name>
<affiliation wicri:level="1"><nlm:affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nakamura, Kyohei" sort="Nakamura, Kyohei" uniqKey="Nakamura K" first="Kyohei" last="Nakamura">Kyohei Nakamura</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Holzel, Michael" sort="Holzel, Michael" uniqKey="Holzel M" first="Michael" last="Hölzel">Michael Hölzel</name>
<affiliation wicri:level="1"><nlm:affiliation>Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2017">2017</date>
<idno type="RBID">pubmed:28759001</idno>
<idno type="pmid">28759001</idno>
<idno type="doi">10.1038/ni.3800</idno>
<idno type="wicri:Area/PubMed/Corpus">000626</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000626</idno>
<idno type="wicri:Area/PubMed/Curation">000624</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000624</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.</title>
<author><name sortKey="Gao, Yulong" sort="Gao, Yulong" uniqKey="Gao Y" first="Yulong" last="Gao">Yulong Gao</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Souza Fonseca Guimaraes, Fernando" sort="Souza Fonseca Guimaraes, Fernando" uniqKey="Souza Fonseca Guimaraes F" first="Fernando" last="Souza-Fonseca-Guimaraes">Fernando Souza-Fonseca-Guimaraes</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bald, Tobias" sort="Bald, Tobias" uniqKey="Bald T" first="Tobias" last="Bald">Tobias Bald</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ng, Susanna S" sort="Ng, Susanna S" uniqKey="Ng S" first="Susanna S" last="Ng">Susanna S. Ng</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Young, Arabella" sort="Young, Arabella" uniqKey="Young A" first="Arabella" last="Young">Arabella Young</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Ngiow, Shin Foong" sort="Ngiow, Shin Foong" uniqKey="Ngiow S" first="Shin Foong" last="Ngiow">Shin Foong Ngiow</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Rautela, Jai" sort="Rautela, Jai" uniqKey="Rautela J" first="Jai" last="Rautela">Jai Rautela</name>
<affiliation wicri:level="1"><nlm:affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Straube, Jasmin" sort="Straube, Jasmin" uniqKey="Straube J" first="Jasmin" last="Straube">Jasmin Straube</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Waddell, Nic" sort="Waddell, Nic" uniqKey="Waddell N" first="Nic" last="Waddell">Nic Waddell</name>
<affiliation wicri:level="1"><nlm:affiliation>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Blake, Stephen J" sort="Blake, Stephen J" uniqKey="Blake S" first="Stephen J" last="Blake">Stephen J. Blake</name>
<affiliation wicri:level="1"><nlm:affiliation>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Yan, Juming" sort="Yan, Juming" uniqKey="Yan J" first="Juming" last="Yan">Juming Yan</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Bartholin, Laurent" sort="Bartholin, Laurent" uniqKey="Bartholin L" first="Laurent" last="Bartholin">Laurent Bartholin</name>
<affiliation wicri:level="1"><nlm:affiliation>Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Lee, Jason S" sort="Lee, Jason S" uniqKey="Lee J" first="Jason S" last="Lee">Jason S. Lee</name>
<affiliation wicri:level="1"><nlm:affiliation>Control of Gene Expression Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Control of Gene Expression Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Vivier, Eric" sort="Vivier, Eric" uniqKey="Vivier E" first="Eric" last="Vivier">Eric Vivier</name>
<affiliation wicri:level="1"><nlm:affiliation>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Takeda, Kazuyoshi" sort="Takeda, Kazuyoshi" uniqKey="Takeda K" first="Kazuyoshi" last="Takeda">Kazuyoshi Takeda</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Cell Biology, Biomedical Research Center and Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.</nlm:affiliation>
<country xml:lang="fr">Japon</country>
<wicri:regionArea>Division of Cell Biology, Biomedical Research Center and Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Messaoudene, Meriem" sort="Messaoudene, Meriem" uniqKey="Messaoudene M" first="Meriem" last="Messaoudene">Meriem Messaoudene</name>
<affiliation wicri:level="1"><nlm:affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Zitvogel, Laurence" sort="Zitvogel, Laurence" uniqKey="Zitvogel L" first="Laurence" last="Zitvogel">Laurence Zitvogel</name>
<affiliation wicri:level="1"><nlm:affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Gustave Roussy Cancer Campus, Villejuif</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Teng, Michele W L" sort="Teng, Michele W L" uniqKey="Teng M" first="Michele W L" last="Teng">Michele W L. Teng</name>
<affiliation wicri:level="1"><nlm:affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>School of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Belz, Gabrielle T" sort="Belz, Gabrielle T" uniqKey="Belz G" first="Gabrielle T" last="Belz">Gabrielle T. Belz</name>
<affiliation wicri:level="1"><nlm:affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Engwerda, Christian R" sort="Engwerda, Christian R" uniqKey="Engwerda C" first="Christian R" last="Engwerda">Christian R. Engwerda</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Huntington, Nicholas D" sort="Huntington, Nicholas D" uniqKey="Huntington N" first="Nicholas D" last="Huntington">Nicholas D. Huntington</name>
<affiliation wicri:level="1"><nlm:affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Nakamura, Kyohei" sort="Nakamura, Kyohei" uniqKey="Nakamura K" first="Kyohei" last="Nakamura">Kyohei Nakamura</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Holzel, Michael" sort="Holzel, Michael" uniqKey="Holzel M" first="Michael" last="Hölzel">Michael Hölzel</name>
<affiliation wicri:level="1"><nlm:affiliation>Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Smyth, Mark J" sort="Smyth, Mark J" uniqKey="Smyth M" first="Mark J" last="Smyth">Mark J. Smyth</name>
<affiliation wicri:level="1"><nlm:affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series><title level="j">Nature immunology</title>
<idno type="eISSN">1529-2916</idno>
<imprint><date when="2017" type="published">2017</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Case-Control Studies</term>
<term>Cell Line, Tumor</term>
<term>Cellular Reprogramming (immunology)</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Fibrosarcoma (immunology)</term>
<term>Flow Cytometry</term>
<term>Gastrointestinal Neoplasms (immunology)</term>
<term>Gastrointestinal Stromal Tumors (immunology)</term>
<term>Gene Expression Profiling</term>
<term>Humans</term>
<term>Immunity, Innate (immunology)</term>
<term>Killer Cells, Natural (cytology)</term>
<term>Killer Cells, Natural (immunology)</term>
<term>Lymphocytes (cytology)</term>
<term>Lymphocytes (immunology)</term>
<term>Mice</term>
<term>Neoplasms, Experimental (immunology)</term>
<term>Sequence Analysis, RNA</term>
<term>Signal Transduction</term>
<term>Transforming Growth Factor beta (immunology)</term>
<term>Tumor Escape (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Analyse de profil d'expression de gènes</term>
<term>Analyse de séquence d'ARN</term>
<term>Animaux</term>
<term>Cellules tueuses naturelles (cytologie)</term>
<term>Cellules tueuses naturelles (immunologie)</term>
<term>Cytométrie en flux</term>
<term>Facteur de croissance transformant bêta (immunologie)</term>
<term>Fibrosarcome (immunologie)</term>
<term>Humains</term>
<term>Immunité innée (immunologie)</term>
<term>Lignée cellulaire tumorale</term>
<term>Lymphocytes (cytologie)</term>
<term>Lymphocytes (immunologie)</term>
<term>Reprogrammation cellulaire (immunologie)</term>
<term>Souris</term>
<term>Test ELISA</term>
<term>Transduction du signal</term>
<term>Tumeurs expérimentales (immunologie)</term>
<term>Tumeurs gastro-intestinales (immunologie)</term>
<term>Tumeurs stromales gastro-intestinales (immunologie)</term>
<term>Échappement de la tumeur à la surveillance immunitaire (immunologie)</term>
<term>Études cas-témoins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Transforming Growth Factor beta</term>
</keywords>
<keywords scheme="MESH" qualifier="cytologie" xml:lang="fr"><term>Cellules tueuses naturelles</term>
<term>Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Killer Cells, Natural</term>
<term>Lymphocytes</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Cellules tueuses naturelles</term>
<term>Facteur de croissance transformant bêta</term>
<term>Fibrosarcome</term>
<term>Immunité innée</term>
<term>Lymphocytes</term>
<term>Reprogrammation cellulaire</term>
<term>Tumeurs expérimentales</term>
<term>Tumeurs gastro-intestinales</term>
<term>Tumeurs stromales gastro-intestinales</term>
<term>Échappement de la tumeur à la surveillance immunitaire</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Cellular Reprogramming</term>
<term>Fibrosarcoma</term>
<term>Gastrointestinal Neoplasms</term>
<term>Gastrointestinal Stromal Tumors</term>
<term>Immunity, Innate</term>
<term>Killer Cells, Natural</term>
<term>Lymphocytes</term>
<term>Neoplasms, Experimental</term>
<term>Tumor Escape</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Case-Control Studies</term>
<term>Cell Line, Tumor</term>
<term>Enzyme-Linked Immunosorbent Assay</term>
<term>Flow Cytometry</term>
<term>Gene Expression Profiling</term>
<term>Humans</term>
<term>Mice</term>
<term>Sequence Analysis, RNA</term>
<term>Signal Transduction</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de profil d'expression de gènes</term>
<term>Analyse de séquence d'ARN</term>
<term>Animaux</term>
<term>Cytométrie en flux</term>
<term>Humains</term>
<term>Lignée cellulaire tumorale</term>
<term>Souris</term>
<term>Test ELISA</term>
<term>Transduction du signal</term>
<term>Études cas-témoins</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Avoiding destruction by immune cells is a hallmark of cancer, yet how tumors ultimately evade control by natural killer (NK) cells remains incompletely defined. Using global transcriptomic and flow-cytometry analyses and genetically engineered mouse models, we identified the cytokine-TGF-β-signaling-dependent conversion of NK cells (CD49a(-)CD49b(+)Eomes(+)) into intermediate type 1 innate lymphoid cell (intILC1) (CD49a(+)CD49b(+)Eomes(+)) populations and ILC1 (CD49a(+)CD49b(-)Eomes(int)) populations in the tumor microenvironment. Strikingly, intILC1s and ILC1s were unable to control local tumor growth and metastasis, whereas NK cells favored tumor immunosurveillance. Experiments with an antibody that neutralizes the cytokine TNF suggested that escape from the innate immune system was partially mediated by TNF-producing ILC1s. Our findings provide new insight into the plasticity of group 1 ILCs in the tumor microenvironment and suggest that the TGF-β-driven conversion of NK cells into ILC1s is a previously unknown mechanism by which tumors escape surveillance by the innate immune system.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28759001</PMID>
<DateCreated><Year>2017</Year>
<Month>07</Month>
<Day>31</Day>
</DateCreated>
<DateCompleted><Year>2017</Year>
<Month>09</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>09</Month>
<Day>11</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1529-2916</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>18</Volume>
<Issue>9</Issue>
<PubDate><Year>2017</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Nature immunology</Title>
<ISOAbbreviation>Nat. Immunol.</ISOAbbreviation>
</Journal>
<ArticleTitle>Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.</ArticleTitle>
<Pagination><MedlinePgn>1004-1015</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1038/ni.3800</ELocationID>
<Abstract><AbstractText>Avoiding destruction by immune cells is a hallmark of cancer, yet how tumors ultimately evade control by natural killer (NK) cells remains incompletely defined. Using global transcriptomic and flow-cytometry analyses and genetically engineered mouse models, we identified the cytokine-TGF-β-signaling-dependent conversion of NK cells (CD49a(-)CD49b(+)Eomes(+)) into intermediate type 1 innate lymphoid cell (intILC1) (CD49a(+)CD49b(+)Eomes(+)) populations and ILC1 (CD49a(+)CD49b(-)Eomes(int)) populations in the tumor microenvironment. Strikingly, intILC1s and ILC1s were unable to control local tumor growth and metastasis, whereas NK cells favored tumor immunosurveillance. Experiments with an antibody that neutralizes the cytokine TNF suggested that escape from the innate immune system was partially mediated by TNF-producing ILC1s. Our findings provide new insight into the plasticity of group 1 ILCs in the tumor microenvironment and suggest that the TGF-β-driven conversion of NK cells into ILC1s is a previously unknown mechanism by which tumors escape surveillance by the innate immune system.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gao</LastName>
<ForeName>Yulong</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Souza-Fonseca-Guimaraes</LastName>
<ForeName>Fernando</ForeName>
<Initials>F</Initials>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bald</LastName>
<ForeName>Tobias</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ng</LastName>
<ForeName>Susanna S</ForeName>
<Initials>SS</Initials>
<AffiliationInfo><Affiliation>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Natural Sciences, Griffith University, Nathan, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Young</LastName>
<ForeName>Arabella</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ngiow</LastName>
<ForeName>Shin Foong</ForeName>
<Initials>SF</Initials>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Rautela</LastName>
<ForeName>Jai</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Straube</LastName>
<ForeName>Jasmin</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Waddell</LastName>
<ForeName>Nic</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Medical Genomics, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Blake</LastName>
<ForeName>Stephen J</ForeName>
<Initials>SJ</Initials>
<AffiliationInfo><Affiliation>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yan</LastName>
<ForeName>Juming</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bartholin</LastName>
<ForeName>Laurent</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Jason S</ForeName>
<Initials>JS</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0003-0879-934X</Identifier>
<AffiliationInfo><Affiliation>Control of Gene Expression Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Vivier</LastName>
<ForeName>Eric</ForeName>
<Initials>E</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-7022-8287</Identifier>
<AffiliationInfo><Affiliation>Centre d'Immunologie de Marseille-Luminy, Aix Marseille Université, INSERM, CNRS, Marseille, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Takeda</LastName>
<ForeName>Kazuyoshi</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Division of Cell Biology, Biomedical Research Center and Department of Biofunctional Microbiota, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Messaoudene</LastName>
<ForeName>Meriem</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>INSERM U1015, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zitvogel</LastName>
<ForeName>Laurence</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>University Paris-Saclay, Kremlin Bicêtre, Paris, France.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>CIC1428, Gustave Roussy Cancer Campus, Villejuif, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Teng</LastName>
<ForeName>Michele W L</ForeName>
<Initials>MWL</Initials>
<AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Cancer Immunoregulation and Immunotherapy, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Belz</LastName>
<ForeName>Gabrielle T</ForeName>
<Initials>GT</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-9660-9587</Identifier>
<AffiliationInfo><Affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Engwerda</LastName>
<ForeName>Christian R</ForeName>
<Initials>CR</Initials>
<AffiliationInfo><Affiliation>Immunology and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Huntington</LastName>
<ForeName>Nicholas D</ForeName>
<Initials>ND</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0002-5267-7211</Identifier>
<AffiliationInfo><Affiliation>Molecular Immunology Division, The Walter and Eliza Hall Institute of Medical Research, Department of Medical Biology and The University of Melbourne, Parkville, Victoria, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Nakamura</LastName>
<ForeName>Kyohei</ForeName>
<Initials>K</Initials>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hölzel</LastName>
<ForeName>Michael</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Unit for RNA Biology, Department of Clinical Chemistry and Clinical Pharmacology, University of Bonn, Bonn, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Smyth</LastName>
<ForeName>Mark J</ForeName>
<Initials>MJ</Initials>
<Identifier Source="ORCID">http://orcid.org/0000-0001-7098-7240</Identifier>
<AffiliationInfo><Affiliation>Immunology in Cancer and Infection, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>School of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2017</Year>
<Month>07</Month>
<Day>31</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Nat Immunol</MedlineTA>
<NlmUniqueID>100941354</NlmUniqueID>
<ISSNLinking>1529-2908</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016212">Transforming Growth Factor beta</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cytokine Growth Factor Rev. 2002 Apr;13(2):95-109</RefSource>
<PMID Version="1">11900986</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2016 Aug 19;17 (9):1025-36</RefSource>
<PMID Version="1">27540992</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2013 Apr 18;38(4):769-81</RefSource>
<PMID Version="1">23453631</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50</RefSource>
<PMID Version="1">16199517</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Apr 17;508(7496):397-401</RefSource>
<PMID Version="1">24509713</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2012 Oct;11(10):790-811</RefSource>
<PMID Version="1">23000686</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2013 May 1;41(10):e108</RefSource>
<PMID Version="1">23558742</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Trends Immunol. 2010 Jun;31(6):220-7</RefSource>
<PMID Version="1">20538542</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Commun. 2014 Aug 14;5:4539</RefSource>
<PMID Version="1">25119382</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Signal. 2016 Feb 16;9(415):ra19</RefSource>
<PMID Version="1">26884601</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncotarget. 2015 May 30;6(15):13835-43</RefSource>
<PMID Version="1">26079948</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5262-70</RefSource>
<PMID Version="1">17875754</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2009 Apr 15;69(8):3563-9</RefSource>
<PMID Version="1">19351841</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2015 Sep 15;75(18):3800-11</RefSource>
<PMID Version="1">26208901</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Syst. 2015 Dec 23;1(6):417-425</RefSource>
<PMID Version="1">26771021</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Mol Immunol. 2014 Nov;11(6):522-37</RefSource>
<PMID Version="1">25066422</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Neoplasia. 2013 Feb;15(2):133-42</RefSource>
<PMID Version="1">23441128</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2009 Nov 1;15(21):6560-9</RefSource>
<PMID Version="1">19861451</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int Immunol. 2001 Apr;13(4):459-63</RefSource>
<PMID Version="1">11282985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Genome Biol. 2014 Feb 03;15(2):R29</RefSource>
<PMID Version="1">24485249</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2016 Jan;16(1):7-19</RefSource>
<PMID Version="1">26694935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):4203-8</RefSource>
<PMID Version="1">24586048</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2016 Feb 15;196 (4):1449-54</RefSource>
<PMID Version="1">26792802</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2016 Jan 28;164(3):365-77</RefSource>
<PMID Version="1">26806130</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Int Immunol. 2016 Jan;28(1):3-11</RefSource>
<PMID Version="1">26346810</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2006 Feb 1;176(3):1582-7</RefSource>
<PMID Version="1">16424187</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2015 Nov;3(11):1207-17</RefSource>
<PMID Version="1">26198985</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell Cycle. 2016;15(2):196-212</RefSource>
<PMID Version="1">26825227</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2017 Mar;23 (3):368-375</RefSource>
<PMID Version="1">28165478</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cell. 2014 Apr 10;157(2):340-356</RefSource>
<PMID Version="1">24725403</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Rev Cancer. 2009 May;9(5):361-71</RefSource>
<PMID Version="1">19343034</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Clin Immunol. 2017 Apr;177:50-59</RefSource>
<PMID Version="1">26476139</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Exp Med. 2000 Feb 21;191(4):661-8</RefSource>
<PMID Version="1">10684858</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Sci Signal. 2016 May 03;9(426):ra46</RefSource>
<PMID Version="1">27141930</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2015 May 5;112(18):E2376-84</RefSource>
<PMID Version="1">25901316</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Mar 11;9(3):e90353</RefSource>
<PMID Version="1">24618589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2016 Jul;17 (7):816-24</RefSource>
<PMID Version="1">27213690</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2015 Oct 15;195(8):3937-45</RefSource>
<PMID Version="1">26371244</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2009 Oct;119(10):2954-64</RefSource>
<PMID Version="1">19759514</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Elife. 2014 Jan 01;3:e01659</RefSource>
<PMID Version="1">24714492</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nucleic Acids Res. 2015 Apr 20;43(7):e47</RefSource>
<PMID Version="1">25605792</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(9):e22842</RefSource>
<PMID Version="1">21909397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Dis Model Mech. 2015 Mar;8(3):237-51</RefSource>
<PMID Version="1">25633981</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2016 Jun 21;17 (7):758-64</RefSource>
<PMID Version="1">27328005</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>PLoS Comput Biol. 2008 Nov;4(11):e1000217</RefSource>
<PMID Version="1">18989396</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Commun. 2015 Oct 29;6:8644</RefSource>
<PMID Version="1">26511769</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18324-9</RefSource>
<PMID Version="1">22021440</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3378-83</RefSource>
<PMID Version="1">17360654</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 1991 May 15;146(10):3289-97</RefSource>
<PMID Version="1">1827481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Front Immunol. 2016 Mar 22;7:104</RefSource>
<PMID Version="1">27047491</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Science. 2015 Nov 20;350(6263):981-5</RefSource>
<PMID Version="1">26472762</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 1993 Dec;92(6):2569-76</RefSource>
<PMID Version="1">7504687</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Oncoimmunology. 2013 Feb 1;2(2):e23080</RefSource>
<PMID Version="1">23525357</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11918-23</RefSource>
<PMID Version="1">20547831</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Discov. 2016 Apr;6(4):446-59</RefSource>
<PMID Version="1">26787820</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 May 15;111(10):4997-5007</RefSource>
<PMID Version="1">18337563</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2012 Jun 14;119(24):5758-68</RefSource>
<PMID Version="1">22544698</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2017 Sep;18(9):995-1003</RefSource>
<PMID Version="1">28759002</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Blood. 2002 Sep 1;100(5):1728-33</RefSource>
<PMID Version="1">12176894</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Clin Invest. 2013 Mar;123(3):1371-81</RefSource>
<PMID Version="1">23454771</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>J Immunol. 2014 Mar 15;192(6):2667-76</RefSource>
<PMID Version="1">24532575</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Immunity. 2016 May 17;44(5):1127-39</RefSource>
<PMID Version="1">27156386</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nat Immunol. 2015 Mar;16(3):306-17</RefSource>
<PMID Version="1">25621825</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Cancer Immunol Res. 2015 Oct;3(10):1109-14</RefSource>
<PMID Version="1">26438443</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Mar 6;507(7490):109-13</RefSource>
<PMID Version="1">24572365</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D065150" MajorTopicYN="N">Cellular Reprogramming</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005354" MajorTopicYN="N">Fibrosarcoma</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005434" MajorTopicYN="N">Flow Cytometry</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005770" MajorTopicYN="N">Gastrointestinal Neoplasms</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046152" MajorTopicYN="N">Gastrointestinal Stromal Tumors</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007694" MajorTopicYN="N">Killer Cells, Natural</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName>
<QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009374" MajorTopicYN="N">Neoplasms, Experimental</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017423" MajorTopicYN="N">Sequence Analysis, RNA</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016212" MajorTopicYN="N">Transforming Growth Factor beta</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019139" MajorTopicYN="N">Tumor Escape</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year>
<Month>04</Month>
<Day>17</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2017</Year>
<Month>06</Month>
<Day>23</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2017</Year>
<Month>8</Month>
<Day>2</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2017</Year>
<Month>9</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2017</Year>
<Month>8</Month>
<Day>1</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">28759001</ArticleId>
<ArticleId IdType="pii">ni.3800</ArticleId>
<ArticleId IdType="doi">10.1038/ni.3800</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000624 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000624 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:28759001
   |texte=   Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:28759001" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a AustralieFrV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Tumor immunoevasion by the conversion of effector NK cells into type 1 innate lymphoid cells.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki